Bifogade filer
PDF
Kalender
| Tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-15 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | N/A | Årsstämma |
| 2025-04-29 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-05 | 08:00 | Bokslutskommuniké 2024 |
| 2024-12-11 | - | Extra Bolagsstämma 2025 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-10-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-15 | - | Extra Bolagsstämma 2023 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2023-05-09 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-08 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-21 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2021-05-04 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2020-05-13 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-17 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-10-31 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-18 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-11 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2018-05-09 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-19 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-05 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2017-05-04 | - | Årsstämma |
| 2017-04-28 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-24 | - | Årsstämma |
| 2016-05-20 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-17 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2015-05-06 | - | Årsstämma |
| 2015-05-06 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | Bokslutskommuniké 2014 |
| 2014-10-30 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-30 | - | Analytiker möte 2014 |
| 2014-07-18 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-09 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2014-05-08 | - | Årsstämma |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-20 | - | Bokslutskommuniké 2013 |
| 2013-11-05 | - | Kapitalmarknadsdag 2013 |
| 2013-11-05 | - | Analytiker möte 2013 |
| 2013-10-30 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-18 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2013-04-26 | - | Årsstämma |
| 2013-04-26 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-10-30 | - | Kvartalsrapport 2012-Q3 |
| 2012-10-30 | - | Analytiker möte 2012 |
| 2012-07-19 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2012-04-26 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-23 | - | Bokslutskommuniké 2011 |
| 2011-11-29 | - | Kapitalmarknadsdag 2011 |
| 2011-10-20 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-24 | - | Extra Bolagsstämma 2011 |
| 2011-07-19 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2011-04-28 | - | Årsstämma |
| 2011-04-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-23 | - | Bokslutskommuniké 2010 |
| 2010-10-26 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-20 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-28 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2010-04-27 | - | Kvartalsrapport 2010-Q1 |
| 2009-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2008-04-25 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2007-05-04 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant exchange rate (CER) (1). Adjusted EBITA margin (1,2) was in the mid-30s per cent of revenues.
The main reasons for the increased revenue are higher sales than expected in Q4 across the Haemophilia portfolio and for Kineret.
- Altuvoct: Higher than expected rate of new patients switching to Altuvoct in markets where the product has been launched, mainly Germany and Switzerland.
- Elocta: Benefited from higher patient numbers across markets and in markets where Altuvoct is launched there were less switches than expected from Elocta. Favorable gross-to-net effects were also observed.
- Alprolix: Higher than expected number of new patients as well as increase in on-demand treatments across Europe.
- Kineret: Higher than expected sales driven mainly by positive gross-to-net adjustments and favorable order phasing but also supported by increased demand.
- The adjusted EBITA margin remained in the expected range as the stronger revenue performance was offset by negative mix effects on the gross margin as well as investments into our launch and pipeline products in the fourth quarter.
At the publication of the Q3 2024 report on 24 October 2024 Sobi stated the outlook for the full year 2024 to be: Revenue was anticipated to grow by a mid-teens percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue.
Sobi will announce its fourth quarter and full year 2024 report on Wednesday 5 February 2025 at 8:00 am CET.
About Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 18:00 CET on 10 January 2025.
Gerard Tobin
Head of Investor Relations
[1] Alternative Performance Measures (APMs).
[2] Excluding items affecting comparability (IAC).